Please assess the completion status of the following clinical trial:

Trial Title: Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of extensive-stage small cell lung cancer (SCLC)~  * No mixed histology~* Presence of ≥ 1 neuroendocrine marker (synaptophysin, chromogranin, or CD56) in tumor tissue~* Achieved partial response (PR), complete response (CR), or stable disease (SD) ≤ 12 weeks of completing 4-6 courses of platinum-based chemotherapy regimen for extensive-stage SCLC~  * Patients with PR or SD must have measurable disease, defined as ≥ 1 lesion whose longest diameter can be accurately measured as ≥ 2.0 cm but \< 10 cm by chest x-ray OR as ≥ 1.0 cm but \< 10 cm by CT scan, CT component of a PET/CT scan, or MRI~    * If CT scan is used, it must be used for both pre- and post-treatment tumor assessments~   * Measurable disease is not required for patients with CR~* Brain metastases allowed provided they have been stable for ≥ 4 weeks after completion of prior radiotherapy~PATIENT CHARACTERISTICS:~* ECOG performance status 0 or 1~* Life expectancy of ≥ 8 weeks~* ANC ≥ 1,500/μL~* Platelet count ≥ 100,000/μL~* Hemoglobin ≥ 9 g/dL~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN) OR direct bilirubin normal~* AST ≤ 3 times ULN (≤ 5 times ULN if liver has tumor involvement)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use adequate contraception~* Able to comply with study procedures to minimize virus exposure to others~* Willing to provide required biologic specimens~* Willing to return to NCCTG/CTSU enrolling institution for follow-up~* Adequate lung function (i.e., not oxygen dependent)~  * The patient is eligible if not on a 24-hour oxygen schedule~* No second primary malignancy within the past 5 years, except for the following:~  * Carcinoma in situ of the cervix~ * Non-melanomatous skin cancer~ * History of low-grade (Gleason score ≤ 6) localized prostate cancer (even if diagnosed \< 5 years prior to study entry)~ * Stage I breast cancer that was treated ≥ 5 years before study entry~ * Transitional cell carcinoma of the bladder (in situ)~* No active hepatitis B or hepatitis C~* No clinically significant infection~* No significant traumatic injury within the past 4 weeks~* No concurrent uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 weeks since prior radiotherapy (2 weeks for palliative radiotherapy to skeletal metastases)~* Other prior radiation therapy (including WBRT, PCI, or Gamma Knife) is permitted as long as the following are true:~  * Recovered from prior radiotherapy (alopecia allowed)~ * No prior consolidation radiation therapy to the chest~ * No prior radiotherapy to \> 25% of bone marrow~ * For patients without brain metastases, WBRT or standard of care PCI completed ≥ 2 weeks before administration of NTX- 010/placebo~* More than 365 days since prior immunotherapy or biologic therapy~* More than 4 weeks since prior major surgery\* (i.e., laparotomy) or open biopsy~* More than 2 weeks since prior minor surgery\*~* No prior exposure to the Seneca Valley virus (NTX-010), as determined by negative serum antibodies~* No concurrent combination antiretroviral therapy for HIV-positive patients NOTE: \*Insertion of a vascular access device is not considered major or minor surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive a single dose of Seneca Valley virus-001 (NTX-010) IV over 1 hour on day 1.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive a single dose of placebo IV over 1 hour on day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy